Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Source:
Nasdaq GlobeNewswire
/
24 Apr 2024 09:00:00 America/New_York
N/A
Share on,